DGAP-News

Sangui BioTech International Inc.: Granulox distribution rights for the UK, Ireland, USA, Canada, Australia and New Zealand granted to infirst HEALTHCARE

DGAP-News: Sangui BioTech International Inc. / Key word(s): Alliance
Sangui BioTech International Inc.: Granulox distribution rights for
the UK, Ireland, USA, Canada, Australia and New Zealand granted to
infirst HEALTHCARE

15.11.2013 / 12:30

---------------------------------------------------------------------

SanguiBioTech: Granulox distribution rights for the UK, Ireland, USA,
Canada, Australia and New Zealand granted to infirst HEALTHCARE

UK sales to start early in 2014

Witten, Germany, November 15, 2013,

infirst HEALTHCARE has been awarded the rights to exclusively market
Granulox in the UK. Ireland, USA, Canada, Australia and New Zealand by
global licensee SastoMed GmbH. Granulox is a patented novel treatment which
is proven to significantly shorten healing time of chronic wounds, and
which holds a Europe-wide medical device license (CE mark). In the UK and
Ireland infirst will start preparing distribution and sales of the wound
therapeutic immediately. A distribution strategy regarding the English
speaking markets overseas will be implemented in due course. This will
include infirst undertaking to obtain the legally required authorizations
to address those markets.

Manfred Scheske, infirst HEALTHCARE's CEO who led Glaxo Smithkline's North
American and European Consumer Healthcare businesses for a combined 12
years, commented: 'Granulox is a perfect fit with our strategic agenda and
we are convinced that this product will contribute to reduce suffering of
patients, improve public health and significantly reduce the associated
healthcare costs.'

infirst HEALTHCARE's commitment is another indication of the market
potential assigned to Granulox by medical and market experts. The company
has the financial strength and management capacities needed to successfully
tackle territories of this size and diversity.

infirst HEALTHCARE is a UK-based healthcare company which spun out of the
SEEK drug discovery group in early 2013. Its developments aim to build on
the trust and safety of well-known drugs and to develop formulations which
result in a genuinely perceived difference in performance. The ultimate
goal is improved and highly effective health management at an early
intervention stage, involving patients, the family practitioners and
pediatricians as well as pharmacists. Among infirst HEALTHCARE's
shareholders is Invesco Perpetual, one of the UK's largest independent
investment funds.

Sangui BioTech International, Inc. ('SGBI') is a holding company the shares
of which are being traded on the OTCQB marketplace (www.otcmarkets.com:
SGBI) and the OTC markets of Berlin and Hamburg-Hannover stock exchanges.
Its purpose is to provide financing and access to the capital markets for
the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent
subsidiary of Sangui BioTech International, Inc.

For more information please contact:

Joachim Fleing
Phone: [phone]
Fax: [phone]
e-mail: [e-mail]


End of financial news

---------------------------------------------------------------------

15.11.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


240175 15.11.2013